3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
52
Thyroid Neoplasms
19
Thyroid Cancer, Papillary
16
Carcinoma, Neuroendocrine
16
Pheochromocytoma
11
Adrenocortical Carcinoma
11
Thyroid Carcinoma, Anaplastic
10
Gastro-enteropancreatic neuroendocrine tumor
10
Small Cell Lung Carcinoma
9
Paraganglioma
9
Multiple Endocrine Neoplasia Type 1
9
Pituitary Neoplasms
8
Lung Neoplasms
8
Adenoma, Islet Cell
8
Sarcoma
7
Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Carcinoma, Medullary
6
Adenocarcinoma, Follicular
6
Colorectal Neoplasms
5
Central Nervous System Neoplasms
5
Carcinoma, Renal Cell
5
Carcinoma, Merkel Cell
5
Carcinoid Tumor
5
Somatostatinoma
4
Pancreatic Neoplasms
4
Neuroblastoma
4
Neoplasm Metastasis
4
Cholangiocarcinoma
4
Carcinoma, Hepatocellular
4
Interventions
entrectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Nephroma, Mesoblastic
×
Endocrine
×
Clear all
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA